NasdaqCM - Delayed Quote • USD
Cidara Therapeutics, Inc. (CDTX)
At close: April 18 at 4:00 PM EDT
After hours: April 18 at 7:59 PM EDT
Earnings Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 3 | -- | 3 | 3 |
| Avg. Estimate | -0.1 | 0 | -0.31 | -0.58 |
| Low Estimate | -0.16 | 0 | -0.36 | -0.7 |
| High Estimate | -0.07 | 0 | -0.28 | -0.38 |
| Year Ago EPS | -0.19 | 0.03 | -0.43 | -0.31 |
Revenue Estimate
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| No. of Analysts | 3 | 2 | 3 | 3 |
| Avg. Estimate | 11.54M | 13.05M | 57.85M | 21.07M |
| Low Estimate | 6.7M | 11.6M | 53M | 5.8M |
| High Estimate | 14M | 14.5M | 60.3M | 29.5M |
| Year Ago Sales | 10.22M | 25.99M | 64.29M | 57.85M |
| Sales Growth (year/est) | 12.90% | -49.80% | -10.00% | -63.60% |
Earnings History
| CURRENCY IN USD | 12/31/2022 | 3/31/2023 | 6/30/2023 | 9/30/2023 |
|---|---|---|---|---|
| EPS Est. | -0.17 | -0.04 | -0.13 | -0.16 |
| EPS Actual | -0.19 | 0.03 | -0.14 | -0.09 |
| Difference | -0.02 | 0.07 | -0.01 | 0.07 |
| Surprise % | -11.80% | 175.00% | -7.70% | 43.80% |
EPS Trend
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Current Estimate | -0.1 | 0 | -0.31 | -0.58 |
| 7 Days Ago | -0.1 | -0.06 | -0.31 | -0.58 |
| 30 Days Ago | -0.1 | -0.06 | -0.31 | -0.58 |
| 60 Days Ago | -0.1 | -0.06 | -0.31 | -0.58 |
| 90 Days Ago | -0.1 | -0.06 | -0.31 | -0.58 |
EPS Revisions
| CURRENCY IN USD | Current Qtr. (Dec 2023) | Next Qtr. (Mar 2024) | Current Year (2023) | Next Year (2024) |
|---|---|---|---|---|
| Up Last 7 Days | -- | -- | -- | -- |
| Up Last 30 Days | -- | -- | -- | -- |
| Down Last 7 Days | -- | -- | -- | -- |
| Down Last 30 Days | -- | -- | -- | -- |
Growth Estimates
| CURRENCY IN USD | CDTX | Industry | Sector | S&P 500 |
|---|---|---|---|---|
| Current Qtr. | 47.40% | -- | -- | 0.80% |
| Next Qtr. | -- | -- | -- | 9.60% |
| Current Year | 27.90% | -- | -- | 4.50% |
| Next Year | -87.10% | -- | -- | 13.30% |
| Next 5 Years (per annum) | 61.20% | -- | -- | 11.09% |
| Past 5 Years (per annum) | -- | -- | -- | -- |
Research Analysis
Analyst Price Targets
Fair Value
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Analyst Recommendations
- Strong Buy
- Buy
- Hold
- Underperform
- Sell
Earnings
Upgrades & Downgrades
| Maintains | HC Wainwright & Co.: Buy to Buy | 4/8/2024 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 12/7/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 11/6/2023 |
| Reiterates | Needham: Buy to Buy | 9/22/2023 |
| Reiterates | HC Wainwright & Co.: Buy to Buy | 9/22/2023 |
| Reiterates | Needham: Buy to Buy | 9/8/2023 |
Related Tickers
TCON TRACON Pharmaceuticals, Inc.
2.1100
-7.86%
NRXP NRx Pharmaceuticals, Inc.
3.0200
-27.58%
EYEN Eyenovia, Inc.
0.5309
-1.56%
CYDY CytoDyn Inc.
0.1509
+3.32%
ARDX Ardelyx, Inc.
6.44
-1.68%
ASLN ASLAN Pharmaceuticals Limited
0.5400
+9.98%
MCRB Seres Therapeutics, Inc.
0.5842
-6.87%
CNTB Connect Biopharma Holdings Limited
1.5200
-1.94%
NRSN NeuroSense Therapeutics Ltd.
1.5200
-5.00%
CELU Celularity Inc.
3.2100
-3.02%